These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 33480963)

  • 1. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.
    Rugo HS; Im SA; Cardoso F; Cortés J; Curigliano G; Musolino A; Pegram MD; Wright GS; Saura C; Escrivá-de-Romaní S; De Laurentiis M; Levy C; Brown-Glaberman U; Ferrero JM; de Boer M; Kim SB; Petráková K; Yardley DA; Freedman O; Jakobsen EH; Kaufman B; Yerushalmi R; Fasching PA; Nordstrom JL; Bonvini E; Koenig S; Edlich S; Hong S; Rock EP; Gradishar WJ;
    JAMA Oncol; 2021 Apr; 7(4):573-584. PubMed ID: 33480963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of margetuximab plus chemotherapy
    Zhang Q; Ouyang Q; Li W; Chiu J; Yan M; Lu YS; Sun S; Li H; Du Y; Wang X; Sun T; Yin Y; Wang H; Ye F; Shen K; Wang J; Pan Y; Wang S; Yang J; Wu X; Dai MS; Cheng J; Teng Y; Su F; Wu X; He J; Fu P; Yang L; Xin Y; Wang X; Jiang Z
    Transl Breast Cancer Res; 2022; 3():31. PubMed ID: 38751523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Huober J; Weder P; Ribi K; Thürlimann B; Thery JC; Li Q; Vanlemmens L; Guiu S; Brain E; Grenier J; Dalenc F; Levy C; Savoye AM; Müller A; Membrez-Antonioli V; Gérard MA; Lemonnier J; Hawle H; Dietrich D; Boven E; Bonnefoi H;
    JAMA Oncol; 2023 Oct; 9(10):1381-1389. PubMed ID: 37561451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial.
    Rugo HS; Im SA; Cardoso F; Cortes J; Curigliano G; Musolino A; Pegram MD; Bachelot T; Wright GS; Saura C; Escrivá-de-Romaní S; De Laurentiis M; Schwartz GN; Pluard TJ; Ricci F; Gwin WR; Levy C; Brown-Glaberman U; Ferrero JM; de Boer M; Kim SB; Petráková K; Yardley DA; Freedman O; Jakobsen EH; Gal-Yam EN; Yerushalmi R; Fasching PA; Kaufman PA; Ashley EJ; Perez-Olle R; Hong S; Rosales MK; Gradishar WJ;
    J Clin Oncol; 2023 Jan; 41(2):198-205. PubMed ID: 36332179
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
    Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
    JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial.
    Cortés J; Diéras V; Lorenzen S; Montemurro F; Riera-Knorrenschild J; Thuss-Patience P; Allegrini G; De Laurentiis M; Lohrisch C; Oravcová E; Perez-Garcia JM; Ricci F; Sakaeva D; Serpanchy R; Šufliarský J; Vidal M; Irahara N; Wohlfarth C; Aout M; Gelmon K
    JAMA Oncol; 2020 Aug; 6(8):1203-1209. PubMed ID: 32584367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
    Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Conte P; Lu Y; Barriga S; Hurt K; Frenzel M; Johnston S; Llombart-Cussac A
    JAMA Oncol; 2020 Jan; 6(1):116-124. PubMed ID: 31563959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.
    Munzone E; Regan MM; Cinieri S; Montagna E; Orlando L; Shi R; Campadelli E; Gianni L; Palleschi M; Petrelli F; Bengala C; Generali D; Collovà E; Puglisi F; Cretella E; Zamagni C; Chini C; Ruepp B; Loi S; Colleoni M;
    JAMA Oncol; 2023 Sep; 9(9):1267-1272. PubMed ID: 37440239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
    Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
    JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.
    Rugo HS; Barve A; Waller CF; Hernandez-Bronchud M; Herson J; Yuan J; Sharma R; Baczkowski M; Kothekar M; Loganathan S; Manikhas A; Bondarenko I; Mukhametshina G; Nemsadze G; Parra JD; Abesamis-Tiambeng ML; Baramidze K; Akewanlop C; Vynnychenko I; Sriuranpong V; Mamillapalli G; Ray S; Yanez Ruiz EP; Pennella E;
    JAMA; 2017 Jan; 317(1):37-47. PubMed ID: 27918780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
    Krop IE; Kim SB; González-Martín A; LoRusso PM; Ferrero JM; Smitt M; Yu R; Leung AC; Wildiers H;
    Lancet Oncol; 2014 Jun; 15(7):689-99. PubMed ID: 24793816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial.
    Hatschek T; Foukakis T; Bjöhle J; Lekberg T; Fredholm H; Elinder E; Bosch A; Pekar G; Lindman H; Schiza A; Einbeigi Z; Adra J; Andersson A; Carlsson L; Dreifaldt AC; Isaksson-Friman E; Agartz S; Azavedo E; Grybäck P; Hellström M; Johansson H; Maes C; Zerdes I; Hartman J; Brandberg Y; Bergh J
    JAMA Oncol; 2021 Sep; 7(9):1360-1367. PubMed ID: 34165503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial.
    Ahn HK; Sim SH; Suh KJ; Kim MH; Jeong JH; Kim JY; Lee DW; Ahn JH; Chae H; Lee KH; Kim JH; Lee KS; Sohn JH; Choi YL; Im SA; Jung KH; Park YH
    JAMA Oncol; 2022 Sep; 8(9):1271-1277. PubMed ID: 35797012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
    Tolaney SM; Barroso-Sousa R; Keenan T; Li T; Trippa L; Vaz-Luis I; Wulf G; Spring L; Sinclair NF; Andrews C; Pittenger J; Richardson ET; Dillon D; Lin NU; Overmoyer B; Partridge AH; Van Allen E; Mittendorf EA; Winer EP; Krop IE
    JAMA Oncol; 2020 Oct; 6(10):1598-1605. PubMed ID: 32880602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.
    Joensuu H; Fraser J; Wildiers H; Huovinen R; Auvinen P; Utriainen M; Villman KK; Halonen P; Granstam-Björneklett H; Tanner M; Sailas L; Turpeenniemi-Hujanen T; Yachnin J; Huttunen T; Neven P; Canney P; Harvey VJ; Kellokumpu-Lehtinen PL; Lindman H
    JAMA Netw Open; 2024 Aug; 7(8):e2429772. PubMed ID: 39186271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial.
    Shao Z; Pang D; Yang H; Li W; Wang S; Cui S; Liao N; Wang Y; Wang C; Chang YC; Wang H; Kang SY; Seo JH; Shen K; Laohawiriyakamol S; Jiang Z; Li J; Zhou J; Althaus B; Mao Y; Eng-Wong J
    JAMA Oncol; 2020 Mar; 6(3):e193692. PubMed ID: 31647503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.